BioSpace News Archive

Paratek Pharmaceuticals, Inc. announced that on February 28, 2023, the Company granted stock options and restricted stock units to four new employees of the Company.

DICE Therapeutics, Inc. (Nasdaq: DICE) today announced that data from its Phase 1 proof-of-concept clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17, will be presented in a late-breaking oral session at the 2023 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 17-21 in New Orleans, LA.

Organogenesis Holdings Inc. (Nasdaq: ORGO) today reported the favorable outcome of the interim analysis of its Phase 3 clinical trial for the management of symptoms associated with knee osteoarthritis.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the fourth quarter and the year ended December 31, 2022.

Biomica, a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at the 2023 ECCO Annual Meeting taking place in Copenhagen, Denmark from March 1 to 4, 2023.

Semler Scientific, Inc. announced the publication of a study in the peer-reviewed Journal of Preventive Medicine with data supporting the use of QuantaFlo as an aid to measure hemodynamics related to heart dysfunction.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 111,250 restricted stock units to eight newly-hired employees.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today reported financial results for the quarter and year ended December 31, 2022, and provided a business update.

Kezar Life Sciences, Inc. announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Autoimmune/Complement/Inflammation panel discussion at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 am ET in Boston, MA.

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced that it will present at the following investor conferences in March.